Accueil   Diary - News   All news ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody

ElsaLys Biotech acquires rights of Transgene’s anti-CD115 antibody

Elsalys logo_vertical_CMJN

 

 

  • Initially developed by Transgene, one of ElsaLys Biotech’s founding shareholders, this antibody inhibits a deleterious subpopulation of macrophages found in the tumor microenvironment.
  • Based on the initial preclinical data, ElsaLys Biotech will give priority to developing ELB 041 (anti-CD115) in immuno-oncology, the goal being to launch a first clinical trial in 24 months.
  • ElsaLys Biotech is now conducting five antibody programs in oncology and ophthalmology.

 

Read the press release